Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® in Gastroesophageal Adenocarcinoma and Zepzelca®
Jazz Pharmaceuticals to Present Research on Epidiolex® and Xywav® Oral Solution at the 2026 American Academy of Neurology Annual Meeting
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026
Ziihera® Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
